Every 424B that Silexion Therapeutics Corp (SLXN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow SLXN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SLXN filings page.
Silexion Therapeutics Corp. disclosed a warrant inducement in a supplement to a prospectus relating to 2,028,619 ordinary shares and 5,932,934 ordinary shares issuable upon exercise of investor, pre-funded and placement agent warrants. Holders agreed to exercise 3,216,928 Existing Warrants for ordinary shares at $0.2603 per share, reduced from $0.65. The Company expects approximately $0.84 million in gross proceeds before placement agent fees and other offering expenses; closing is expected on or about September 29, 2026, subject to customary closing conditions.
In exchange, the Company agreed to issue Series F and Series G warrants for up to an aggregate of 6,433,856 ordinary shares, with each series covering up to 3,216,928 shares, at $0.2603 per share. The new warrants are exercisable upon the effective date of an authorized ordinary-share increase following shareholder approval. The exercise price for all outstanding series E warrants covering 3,846,161 ordinary shares is also reduced to $0.2603 per share.
Silexion Therapeutics Corp, a clinical-stage oncology biotech focused on RNA interference therapies for KRAS-driven cancers, is conducting a best-efforts primary offering of 2,028,619 ordinary shares together with 3,846,161 ordinary warrants at a public offering price of $0.65 per share and accompanying warrant. Purchasers that would otherwise exceed 4.99% or 9.99% beneficial ownership may instead purchase up to 1,817,542 pre-funded warrants at $0.6499 each, each paired with one ordinary warrant. The ordinary warrants have a $0.65 exercise price and a five-year term; the pre-funded warrants are exercisable at $0.0001 per share until fully exercised. Gross proceeds total about $2.50 million, with estimated net proceeds of roughly $2.1 million after placement fees, to be used to advance pre-clinical and clinical studies and for general corporate purposes. The company’s ordinary shares and warrants trade on the Nasdaq Capital Market as “SLXN” and “SLXNW.” Silexion is advancing lead candidate SIL204 for locally advanced pancreatic cancer and has received regulatory clearances in Israel and Germany to initiate a Phase 2/3 trial, which has begun enrollment at an initial Israeli site. The company reports substantial doubt about its ability to continue as a going concern and is also using this financing to help support compliance with Nasdaq shareholders’ equity requirements.
Silexion Therapeutics Corp registers the resale of up to 859,609 ordinary shares by identified selling shareholders, consisting of up to 399,020 shares issuable upon new warrants and placement agent warrants and up to 446,623 shares issuable upon conversion of amounts under a sponsor promissory note. The registration statement notes shareholders’ approval and the effective date of this registration affect when the new warrants and placement agent warrants become exercisable. The company will receive no proceeds from the resale by the selling shareholders but may receive proceeds if holders exercise warrants for cash at exercise prices of $5.00 and $6.25 per share.